1									
2	UVESCREEN1: A randomised feasibility study of imaging-based uveitis screening for								
3	children with juvenile idiopathic arthritis- Study Protocol								
4									
5	Short title: UVESCREEN1 Protocol								
6									
7	Authors: Sonali Dave ¹ , Jugnoo Rahi ^{1,2,3,4,5} , Harry Petrushkin ^{2,4,6} Ilaria Testi ^{2,4,6} , Dipesh E								
8	Patel ^{1,3,4,6} , Ameenat Lola Solebo ^{1,2,3,6}								
9									
10	Affiliations:								
11	1. Population, Policy and Practice Programme, UCL GOS Institute of Child Health,								
12	London, UK								
13	2. Great Ormond Street Hospital for Children NHS Trust, London UK								
14	3. National Institute for Health Research Biomedical Research Centre at Great Ormond								
15	Street Hospital and UCL GOS ICH, London, UK								
16	4. National Institute for Health Research Biomedical Research Centre at Moorfields Eye								
17	Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK								
18	5. Ulverscroft Vision Research Group, London, UK								
19	6. Moorfields Eye Hospital NHS Trust, London, UK								
20									
21	Corresponding author: Ameenat Lola Solebo 0000-0002-8933-586								
22	Postal address: UCL GOS Institute of Child Health, 30 Guilford Street, London, WC1N 1EH,								
23	UK. Email address: <u>a.solebo@ucl.ac.uk</u>								

25 Abstract

26 Children with Juvenile Idiopathic Arthritis (JIA) are at a currently unpredictable risk of a 27 blinding, often asymptomatic, co-existent eye disorder, anterior uveitis which requires prompt 28 treatment. The unpredictability of this insidious disorder commits children with JIA to three-29 monthly expert clinical examination in specialist eve centres often located far from their homes. 30 Optical coherence tomography of the ocular anterior segment (AS-OCT) has been shown to be 31 an acceptable, repeatable and sensitive modality for uveitis detection, but is not standard care. 32 This feasibility randomised controlled trial (RCT) aims to inform a future full-scale RCT 33 comparing current routine practice (expert slit lamp examination, SLE) to AS-OCT for the 34 surveillance of uveitis in children at risk.

Eighty children aged between 2 and 12 years old and diagnosed with JIA within the preceding 35 36 year will be included. Participants with an existing diagnosis of uveitis, other ocular co-37 morbidities or those unable to complete examinations or provide informed assent will be excluded. Participants will be randomised to SLE (control) or AS-OCT (intervention) 38 39 examination at a frequency consistent with the current national programme for childhood 40 uveitis surveillance. Children in the intervention arm will also have standard examination at 6 41 and 12 months after study entrance. Outcomes of interest will be feasibility (recruitment and 42 attrition rates), clinical metrics (proportion diagnosed with uveitis or other ocular disorders at 43 12 months after study entrance), quality of life outcomes (PedsQL), and resource use. Additionally, comparative analysis of AS-OCT versus SLE ('gold standard' reference testing) 44 45 findings at 6 and 12 months for those in the intervention arm will provide the proof-of-concept 46 data necessary to develop and undertake a larger scale trial.

47 Trial registration: This trial has been registered with clinicaltrails.gov (NCT05984758).

48 Summary

49 Anterior uveitis is a rare form of eye disease that is commonly associated with Juvenile 50 Idiopathic Arthritis (JIA). Childhood uveitis is potentially blinding, so children with JIA must 51 travel to a specialist centre every two to three months for an eye examination to pick up signs 52 of uveitis. This feasibility study will compare routine Slit Lamp Examination (SLE) with 53 imaging-based surveillance using Optical Coherence Tomography of the Anterior Segment 54 (AS-OCT) to support the design of a future study. Eighty children between the ages of two 55 and twelve years old who have been diagnosed with JIA in the past year will be invited to 56 take part. Children will be randomised into one of two arms (SLE or AS-OCT) and will have 57 their routine uveitis screening appointments over one year using either of the screening 58 modalities. This study will provide the proof-of-concept data necessary to develop and 59 undertake a larger scale trial.

60 Introduction

61 Childhood uveitis is a rare but significant chronic eve condition [1]. Whist childhood onset 62 disease accounts for approximately 1% of cases seen in adult uveitis clinics [2, 3], it accounts 63 for 10% of cases of uveitis related sight impairment amongst adults [4, 5]. This over-64 representation is compounded by the frequent presence of multisystem disorders amongst those 65 with childhood onset uveitis [6]. A key example is Juvenile Idiopathic Arthritis (JIA), the most 66 common childhood inflammatory arthropathy [7]. Uveitis affecting the front section of the eve 67 (anterior uveitis) the most common extra-articular manifestation of JIA [8] Childhood anterior 68 uveitis can be asymptomatic, or occur in children too young to report symptoms, so children 69 with JIA undergo regular eye surveillance examinations every few months [9].

70

71 The strongest predictor of poor outcomes in childhood onset uveitis is the presence of 72 established ocular structural complications at presentation i.e. delayed diagnosis [10]. The 73 worsening international workforce shortfall in paediatric ophthalmology is an obstacle to 74 timely diagnosis for this population [11]. Imaging-based disease surveillance, which could be 75 undertaken in settings across primary to tertiary care [12], would address this shortfall in 76 capacity, providing specialist level care (potentially closer to the child's home) to facilitate 77 timely diagnosis and reduce the burden of uveitis related visual impairment amongst children 78 and the adults they become.

79

Optical Coherence Tomography (OCT) machines have been widely adopted in secondary care and primary care settings (including high street opticians), providing high resolution images of eye structures [13]. OCT of the anterior segment (AS-OCT) to detect inflammatory cells in the eye, the hallmark of anterior uveitis, has been shown to be repeatable and highly sensitive for childhood disease [14]. Work has also been undertaken to understand the normative findings

in healthy children [15]. The implementation of this potentially transformational innovationneeds robust evidence on safety and effectiveness.

87 We aim to begin to provide the necessary high-level evidence, through a feasibility randomised 88 controlled trial of AS-OCT versus routine clinical examination for the detection of uveitis in 89 children at risk. This proof-of-concept study will compare imaging-based surveillance to the 90 current approach of clinical examination (slit lamp examination-based surveillance) in the detection of uveitis in children with juvenile idiopathic arthritis The proposed study will 91 92 provide the data needed to develop eligibility criteria, recruitment and retention approaches, to 93 determine the key outcome metrics and study sample size necessary to demonstrate non-94 inferiority, and to inform the selection of the resource use measures needed to determine cost-95 effectiveness.

96

97 Materials and Methods

98 The proposed study has been designed in line with the SPIRIT (Standard Protocol Items:99 Recommendations for Interventional Trials) guidelines [16].

100

101 Study design

102 This study will be a two-arm, parallel group, single site feasibility randomised controlled trial

103 (RCT) comparing slit lamp examination-based (SLE, routine care) with AS-OCT based

104 detection of active anterior chamber inflammation over 52 weeks in children undergoing

surveillance examinations for juvenile idiopathic associated uveitis. Study participants will be

- 106 children newly diagnosed (within the preceding 12 months) with JIA. The primary outcomes
- 107 will be study feasibility metrics (i.e. recruitment and attrition rates). Proof of concept
- analyses will also be undertaken, with comparison of AS-OCT assessment to 'gold standard'
- 109 clinical examination at 6 and 12 months.

110

111 Setting

- 112 This will be a single site study, undertaken within a tertiary/quaternary healthcare setting:
- 113 Great Ormond Street Hospital (GOSH), England, UK. Participants will be identified and
- 114 recruited on attendance to routine outpatient appointments.

115

116 Participants

- 117 Eligibility criteria comprise:
- New diagnosis (within preceding 12 months) of JIA
- Eligible for uveitis surveillance in line with national guidance (table 1) [9]
- Aged between 2 and 12 years

121 Exclusion criteria comprise:

Visual impairment or any ocular co-morbidities that would negatively impact on best corrected acuity
Developmental/learning difficulties that preclude concordance with examination/informed assent

perpetuity. It is made available under a CC-BY 4.0 International license .

First eye examination within 6 weeks of referral								
Two monthly intervals from onset of arthritis for 6 months								
Then 3-4 monthly eye examinations for time outlined below:								
Age at onset	Length of surveillance							
Less than 3 years ^a	8 years							
3-4 years ^a	6 years							
5-8 years ^a	3 years							
9-10 years ^a	1 year							
Less than 6 years ^b	5 years							
6-9 years ^b	2 years							
Any age ^c	5 years							

- **Table 1-** Guidelines for screening for uveitis in JIA by the Royal College of
- 128 Ophthalmologists and the British Society for Paediatric and Adolescent Rheumatology129 (BSPAR).
- 130 ^a- For oligoarticular JIA, Psoriatic arthritis onset and Enthesitis related arthritis (ERA)
- 131 ^b- For polyarticular, ANA+ JIA onset < 10 years
- 132 ^c- For polyarticular, ANA- JIA, onset <7 years
- 133

134 Study intervention - AS-OCT

135 Children randomised to the intervention arm will undergo AS-OCT imaging to detect anterior

136 chamber inflammation. The AS-OCT images will be acquired using the Optovue RTVue OCT

137 (8 cross-sectional scans) and the Heidelberg Spectralis OCT2 machines (anterior segment cube

scan). Images will undergo manual analysis by a trained clinician to identify the presence of

139 inflammatory cells within the anterior chamber. A later semi-automated re-analysis of acquired

140 images will be undertaken within one week of the examination using published protocols [12,

141 14]. Full details of image acquisition and analysis processes are available in supplemental

142 document 1 (S1).

143

Imaging will be undertaken at a frequency consistent with line with national guidance (table 1)
[9]. This comprises 6 study visits in total (at Month 2 following the first visit to establish
eligibility, Month 4, Month 6, Month 9, and Month 12- see table 1 for further details). The full
participant schedule of assessments is shown in figure 1, with specific details of the study
procedures shown in figure 2.

Exit from the study will occur either at visit 7 (for participants with a new diagnosis of JIA within 6 months of entrance to study), at visit 6 (for participants whose JIA was diagnosed within 6 to 12 months of study entrance, figure 1), or at any visit where uveitis has been diagnosed. A diagnosis of uveitis will be made clinically, using slit lamp examination. Any child within the intervention arm in whom a 'disease positive' AS-OCT is acquired (i.e. more than 1 hyper-reflective particle in any cross-sectional scan) will undergo a confirmatory slit lamp examination. Confirmation of uveitis will lead to a child exiting the study.

- 158 Figure 1- SPIRIT schedule of assessments.
- 159 ^a Visits for those within 6 months of diagnosis: newly diagnosed: Day 1, Week 8, Week 16,
- 160 Week 28, Week 40, last visit Week 52
- 161 Visits for those entering study outside the 6-month widow: Day 1, Week 13, Week 26, Week 162 39. Week 52
- 163 ^b Concomitant use of a. immunosuppression or immunomodulation (and dose); any eye or
- 164 visual symptoms since last visit; any other parental concerns
- 165 ^c Measured with age-appropriate method: Cardiff cards, Thomson Kays or Thomson
- *LogMAR in each eye separately* 166
- 167 ^{*d*} Heidelberg Spectralis OCT2 and Optovue RTVue anterior segment cube and single line
- 168 scans
- 169 ^eA diagnosis of new onset uveitis at any visit results in exit from the trial
- 170
- 171 Figure 2- Details about the specific procedures during the intervention and control arm. *-
- 172 See supplemental document 2 (S2) for specific visual acuity screening protocol
- 173
- 174 Study outcome measures
- 175 The main outcomes of interest are the study feasibility metrics, specifically
- 176 - The proportion of patients within the service who meet the eligibility criteria, and reasons for
- exclusion 177
- 178 - The proportion of eligible patients recruited
- 179 - The proportion of patients who withdraw due to loss of consent or are lost to follow-up
- 180 - Statistical parameters (point estimates and range / variance) of the clinical and patient centred
- 181 outcome measures
- 182 The primary clinical outcome measured (as a surrogate endpoint) will be:
- 183 - Agreement, for participants in the intervention arm, of AS-OCT findings with routine clinical
- 184 examination, analysed at 6 months and 12 months milestones
- 185 Other clinical outcomes of interest will be:
- 186 - New diagnosis of uveitis
- 187 - New diagnosis of other visual/ocular problems
- 188 We shall be evaluating patient centred outcomes, specifically

- Health related quality of life (PedsQL child self-report, at 12 months and change from

- 190 baseline to 12 months)
- 191 We shall also be evaluating resource use across the feasibility study to support the design of
- 192 cost-effectiveness analyses in the larger scale study.
- 193
- 194 Adverse and serious adverse events (AE/SAE) will be recorded for both the intervention and
- 195 routine care arms. These events comprise (1) Development of anterior chamber
- 196 inflammation; (2) development of non-sight threatening sequalae of ocular inflammation
- during the study period; (3) progression or disease flare of JIA; (4) development of treatment
- 198 related adverse events. AE/SAE occurring in the intervention arms will be used as criteria to
- determine progression to a full RCT. Specifically. the progression criteria will be defined
- 200 using a 'traffic-light' system (green criteria met, amber minor changes needed, red -
- 201 significant changes needed).
- 202 Recruitment
- **203** Green >4 recruits/month
- 204 Yellow 2-4 recruits/month
- 205 Red <2 recruits/month

Adverse events (incidence of sight threatening complications in imaging-based surveillance

- 207 group)
- 208 Green / Yellow No cases
- **209** Red ->1 case
- 210 Adherence to surveillance programme
- **211** Green >75%
- **212** Yellow 30-75%
- **213** Red <30%

214

215 Sample size

As a feasibility study, there is no formal power calculation based on clinical non-inferiority for a diagnostic intervention [17]. To 'quantify' and assess the concept that imaging-based surveillance is not inferior to clinical slit-lamp examination in the detection of active anterior uveitis in children at risk, the starting point will be that that SLE findings (assumed to be abnormal in 100% of children with an active anterior uveitis) and AS-OCT findings will concord in at least 95%.

222

223 Recruitment

224 Following identification through medical record review and confirmation of eligibility at 225 routine clinical review, participants will be approached postally, using posted participant 226 information sheets, or by telephone, 1-2 weeks prior to the next planned outpatient attendance. 227 Informed consent will be sought by a member of the research team within a week of being 228 given the study documentation. Assent will also be sought from participating children where 229 appropriate [18, 19] (see supplemental material 3 (S3) for the consent and assent forms to be 230 used in the study). To minimise participant attrition, after entering the trial families will receive 231 telephone calls a few days ahead of each visit to support attendance, and financial support for 232 travel costs.

233

234 Randomisation and allocation

Coordinated registration and allocation of participant trial numbers will be used. Participants
will be allocated using computer-generated permuted block randomisation into one of two arms
(1:1, block size= 4) stratified by age (8 and under, over 8). This will be undertaken centrally
by the coordinating trial team using Sealed envelope (www.sealedenvelope.com). Allocation

- will not be concealed, and participants cannot be masked to their allocation to routine (slit lampexamination) or imaging-based surveillance (AS-OCT) examinations.
- 241

242 Data collection and processing

- 243 Data will be entered into electronic data collection forms (DCFs) using the REDCap platform,
- with collection undertaken during study visits by research associates or clinicians and reviewed
- for completeness by an investigator. Alongside the data collection forms, optical coherence
- tomography (OCT) images will be collected from participants.
- 247 To limit data missingness, the following approaches will be used:

- Validation rules within the REDCap form (i.e. form submission will not be permitted if data

- entry points have not been completed)
- 250 Incoming data review monthly by the study team and screening committee to identify
 251 missingness, and any patterns of / reasons for missingness within the study dataset
- 252 Exclusion from outcomes analysis of participants lacking a full dataset for more than two253 consecutive study visits

254 Patient data will not be transferred to any party not identified in this protocol and will not to be 255 processed and/or transferred other than in accordance with the patients' consent. Direct access 256 to the data will be granted to authorised representatives from the Sponsor, host institution and 257 the regulatory authorities to permit study-related monitoring, audits and inspections. This trial 258 will collect personal data (e.g. participant names), including special category personal data (e.g. 259 participant medical information) and this will be handled in accordance with all applicable data 260 protection legislation. Data (including special category) will only be collected, used and stored 261 if necessary for the trial. The database and randomisation system will be designed to protect 262 patient information in line with the GDPR. All documents will be stored securely and only 263 accessible by study staff and authorised personnel.

264

265 Analysis

266 Proportions will be reported as point estimates with 95% confidence intervals. Levels of 267 missing data will be explored with respect to certain baseline characteristics, e.g. age and 268 measures of disease severity to assess biases. All harms or unintended effects in each group 269 will be reported. Effect size (of 'discrimination' of disease) and variability in outcomes will be 270 estimated with 95% confidence intervals to inform the sample size calculations for a full-scale 271 trial. Initial trial success will be defined as: recruitment rates of >4 recruits/month, or 272 generation of information on barriers to recruitment; adverse event (incidence of new sight 273 threatening complications in imaging-based surveillance group) rate of 0; adherence to 274 surveillance programme of >75% or understanding of barriers to adherence. We will seek to 275 identify potential cost drivers to inform the collection of the data for cost-effectiveness analyses 276 within a future definitive study.

277

278 Data monitoring

This study will be overseen by a study steering committee (SC). The UVESCREEN1 SC will consist of the Chief Investigator, trial staff, and invited members who represent clinical, clinical researcher, and patient stakeholders. The SC will review interim analysis of recruitment figures, adverse and serious adverse events, trial conduct and any substantial amendments to the protocol. The committee will meet 2-3 times a year.

284

The Chief Investigator will be responsible for the day-to-day monitoring and management of the study. The Chief Investigator will ensure there is adequate monitoring of activities conducted by the study team. This will include adherence to the protocol, procedures for consenting and adequate data quality. The Chief Investigator will inform the Sponsor if there

are concerns that have arisen from monitoring activities, and/or if there are problems with oversight/monitoring procedures. Any changes to the protocol including changes to the eligibility criteria, outcomes or analysis will be reported to the study team, sponsor and REC by the chief investigator.

293

- 294 Ethics considerations and declarations
- 295 This study had received ethics approval from Yorkshire & The Humber Leeds West
- 296 Research Ethics Committee (REF 23/YH/0237, accepted protocol version V2, date
- 297 18/10/2023). The study will be carried out in accordance with the Declaration of Helsinki and
- all participants will provide written or electronic informed consent.
- 299

300 Patient and Public Involvement (PPI)

The development of this study has been supported by a patient expert group, the Childhood
Uveitis Study steering group [20, 21]. This proposal is also driven by the priorities identified
by stakeholders (patients and professional groups) who participated in the 2013 James Lind
Alliance Priority Setting Partnership (JLA PSP) [22].

305

306 Dissemination

We estimate participant recruitment to be completed by April 2026 with data collection to be completed by October 2026. Results will be analysed and disseminated approximately six months later. Findings will be disseminated through journal articles and presentations at both academic and medical conferences. Contributors to (i) the design, conduct, data analysis and interpretation, (ii) writing, (iii) manuscript approval and (iv) accountability for the integrity of the work will, depending on their contribution and journal requirements, will be included by name at the manuscript head. The Uniform Requirements for Manuscripts Submitted to Biomedical Journals (http://www.icmje.org/) will be respected in manuscripts generated by this study. At the end of the trial, after the primary results have been published, the anonymised individual participant data (IPD) and associated documentation (e.g. protocol, statistical analysis plan, annotated blank CRF) will be prepared in order to be shared with external researchers.

319

320 Discussion

321 This feasibility, proof-of-concept RCT will compare imaging-based surveillance to routine 322 clinical examination in the detection of uveitis in children at risk, providing the information 323 necessary for the design of a future study. This information will comprise feasibility data 324 needed to finalise eligibility criteria, recruitment and retention approaches, and data to 325 determine the key outcome metrics and study sample size necessary to demonstrate non-326 inferiority, and the resource use measures needed to determine cost-effectiveness. Study 327 findings are intended to inform the development of a full scale RCT to determine whether 328 imaging-based uveitis surveillance is non-inferior to routine surveillance with regards to 329 detection of childhood anterior uveitis in those at risk. Qualitative interviews will also be 330 completed with selected participants (n=10) to establish acceptability amongst participants and 331 families and to aid implementation into practice. Longer term impact will be evaluated through 332 the planned full-scale trial.

333

Attempts to ensure timely diagnosis of childhood uveitis are frustrated by the worsening shortfall in the number of appropriately trained specialists. In some areas of the United Kingdom, children with juvenile idiopathic arthritis are not accessing ophthalmic care within the recommended time window [23]. Across the UK, there is a workforce crisis in paediatric ophthalmology [11]. This crisis is replicated globally [24]. The wide community adoption of

339 OCT provides a platform for the use of AS-OCT to address some of these challenges. 340 Specifically, the use of AS-OCT detection of active anterior uveitis would release patients from 341 the need to attend hospital eye specialist clinics, as imaging could be undertaken in community 342 eve health centres. The findings from this proposed research project would support the future 343 implementation of hospital and community based anterior segment imaging-based uveitis 344 surveillance for populations at particular risk but would also be the foundation of future 345 imaging-based surveillance at whole population level. They also provide a chance to put 346 children first, with childhood disease driving the science and implementation, and supporting 347 later wider adoption for adult uveitis. Adult disease is common relative to childhood uveitis 348 (incidence 17-52.4 per 100,000 versus incidence 2-20 per 100,000) [25, 26], is a major cause 349 of working age blindness [27] and is the most common cause of attendance to acute eye care 350 services [28].

351 There are limitations inherent in the design of the proposed study. Firstly, due to the study 352 design, it is not possible for the participants and research team to be masked to the arm to which 353 participants have been allocated, and this may introduce the risk of researcher bias. Equally, 354 due to the nature of the intervention, it is not possible for study participants to be masked to 355 their study arm, which also potentially risks information bias in patient reported outcomes. A 356 pragmatic design, in which each child undertook both standard and interventional examination, 357 with randomisation of which examination would be used for assessment, may be the approach 358 taken for future studies, informed by the findings of this feasibility trial. Secondly, recruitment 359 will only take place at a single site, potentially limiting the generalisability of the data. 360 Additionally, this site is a highly specialised care setting, with participants poorly 361 representative of the 'average' patient. Again, as this is a feasibility study, informing a future 362 larger scale study, there will be exploration and description of the representativeness of the 363 recruited patient sample, and reflection of how that compares to what is known about the

364 characterises of the wider population of children at risk. Participants in this study will be
365 reimbursed for their travel and will consent to regular phone calls to support attendance. As
366 this deviates from routine care, it can be argued that this reduces the generalisability of the
367 study. However, the findings from this study will provide a baseline for best achievable attrition
368 rate to as comparison for the full RCT, where generalisability will be considered again.

369

370 In conclusion, this study will provide vital information about the feasibility of conducting a

arger scale trial on SLE versus AS-OCT uveitis screening examinations for children with JIA.

372 The data collected in this study will also provide valuable insight into the practical

- 373 considerations needed before implementing this into a larger scale RCT.
- 374

375 Authors' contributions

- 376 Conceptualization: ALS
- 377 Writing- Original draft and Preparation: ALS and SD
- 378 Writing Review & Editing: ALS, SD, JR, HP, DEP, IT
- 379 Methodology: ALS
- 380 Visualization: ALS and SD
- 381

382 Data Availability

383 No datasets were generated or analysed during the current study.

- 385 Acknowledgements We thank the Childhood Uveitis (patient expert) Studies steering group
- **386** for their support.
- 387

389 **References**

- 390 1. Smith JA, Mackensen F, Sen HN, Leigh JF, Watkins AS, Pyatetsky D, et al.
- **391** Epidemiology and course of disease in childhood uveitis. Ophthalmology. 2009;116(8):
- **392** 1544-51. doi:10.1016/j.ophtha.2009.05.002.
- 393 2. Hart CT, Zhu EY, Crock C, Rogers SL, Lim LL. Epidemiology of uveitis in urban
- **394** Australia. Clin Exp Ophthalmol. 2019;47(6): 733-40. doi: 10.1111/ceo.13517.
- 395 3. Jones NP. The Manchester Uveitis Clinic: the first 3000 patients--epidemiology and
 396 casemix. Ocul Immunol Inflamm. 2015;23(2): 118-26. doi: 10.3109/09273948.2013.855799.
- 397 4. Bodaghi B, Cassoux N, Wechsler B, Hannouche D, Fardeau C, Papo T, et al. Chronic
- severe uveitis: etiology and visual outcome in 927 patients from a single center. Medicine.
- **399** 2001;80(4): 263-70. doi: 10.1097/00005792-200107000-00005.
- 400 5. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and
- 401 frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol.
- **402** 1996;80(4): 332-6. doi: 10.1136/bjo.80.4.332.
- 403 6. Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic
 404 arthritis: functional outcome. Rheumatology. 2002;41(12): 1428-35.
- doi:10.1093/rheumatology/41.12.1428.
- 406 7. Costello A, Rasooly I, Weiss P. Rheum for Improvement? Delayed Diagnosis of
 407 Juvenile Idiopathic Arthritis: A Narrative Review. Arthritis Care Res (Hoboken). 2024. doi:
 408 10.1002/acr.25438.
- 409 8. Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. Clin Immunol.
 410 2020;211. doi: 10.1016/j.clim.2019.108322.
- 411 9. Guidelines for screening for uveitis in juvenile idiopathic arthritis (JIA) [Internet].
- 412 The Royal College of Ophthalmologists. 2006 [cited 2024 Dec 10]. Available from:
- $\label{eq:2.1} 413 \qquad https://www.rcophth.ac.uk/resources-listing/guidelines-for-screening-for-uveitis-in-juvenile-in-juvenil$
- 414 idiopathic-arthritis-jia/.
- 415 10. Gregory AC, 2nd, Kempen JH, Daniel E, Kaçmaz RO, Foster CS, Jabs DA, et al. Risk
- 416 factors for loss of visual acuity among patients with uveitis associated with juvenile
- 417 idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study.
- 418 Ophthalmology. 2013;120(1): 186-92. doi: 10.1016/j.ophtha.2012.07.052.
- 419 11. New RCOphth Workforce Census illustrates the severe shortage of eye doctors in the
- 420 UK [Internet]. The Royal College of Ophthalmologists. 2019 [cited 2024 Dec 10]. Available

- 421 from: https://www.rcophth.ac.uk/news-views/new-rcophth-workforce-census-illustrates-the-
- 422 severe-shortage-of-eye-doctors-in-the-uk/
- 423 12. Akbarali S, Rahi JS, Dick AD, Parkash K, Etherton K, Edelsten C, et al. Imaging-
- 424 Based Uveitis Surveillance in Juvenile Idiopathic Arthritis: Feasibility, Acceptability, and
- 425 Diagnostic Performance. Arthritis Rheumatol. 2021;73(2): 330-5. doi: 10.1002/art.41530.
- 426 13. Liu X, Solebo AL, Faes L, Beese S, Braithwaite T, Round ME, et al. Instrument-
- 427 based Tests for Measuring Anterior Chamber Cells in Uveitis: A Systematic Review. Ocul
- 428 Immunol Inflamm. 2020;28(6): 898-907. doi: 10.1080/09273948.2019.1640883.
- 429 14. Etherton K, Rahi JS, Petrushkin H, Dick AD, Akbarali S, Pattani R, et al. Quantitative
- 430 and qualitative assessment of anterior segment optical coherence tomography capture of
- disease state in childhood anterior uveitis. Br J Ophthalmol. 2023;107(7): 966-72. doi:
- **432** 10.1136/bjophthalmol-2021-320448.
- 433 15. Solebo AL, Bellchambers A, Kellett S, Rahi JS, Dick AD. Establishing the Normative
- 434 Data Set Necessary for Imaging-Based Childhood Uveitis Surveillance: A Cross-Sectional
- 435 Study. Invest Ophthalmol Vis Sci. 2024;65(1):9. doi:10.1167/iovs.65.1.9.
- 436 16. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al.
 437 SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med.
 438 2013;158(5): 200-7. doi: 10.7326/0003-4819-158-3-201302050-00583.
- Totton N, Lin J, Julious S, Chowdhury M, Brand A. A review of sample sizes for UK
 pilot and feasibility studies on the ISRCTN registry from 2013 to 2020. Pilot Feasibility Stud.
 2023;9(1):188. doi: 10.1186/s40814-023-01416-w
- 442 18. Oulton K, Gibson F, Sell D, Williams A, Pratt L, Wray J. Assent for children's
 443 participation in research: why it matters and making it meaningful. Child Care Health Dev.
 444 2016;42(4): 588-97. doi: 10.1111/cch.12344.
- Tait AR, Geisser ME. Development of a consensus operational definition of child
 assent for research. BMC Med Ethics. 2017;18(1):41. doi: 10.1186/s12910-017-0199-4.
- 447 20. Kellett S, Rahi JS, Dick AD, Knowles R, Tadić V, Solebo AL. UNICORNS: Uveitis
- 448 in childhood prospective national cohort study protocol. F1000Res. 2020;9:1196. doi:
- 449 10.12688/f1000research.26689.2.
- 450 21. Solebo AL, Kellett S. Inclusive study design to better serve the needs of children and
- 451 young people with rheumatological conditions. Lancet Rheumatol. 2024;6(11):e746. doi:
- **452** 10.1016/S2665-9913(24)00271-6.
- 453 22. Rowe F, Wormald R, Cable R, Acton M, Bonstein K, Bowen M, et al. The Sight Loss
- and Vision Priority Setting Partnership (SLV-PSP): overview and results of the research

- 455 prioritisation survey process. BMJ Open. 2014;4(7):e004905. doi: 10.1136/bmjopen-2014456 004905.
- 457 23. Angeles-Han ST, Srivastava SK. Screening, Monitoring, and Treating Children With
- **458** Juvenile Idiopathic Arthritis-associated Uveitis: Visualizing Better Outcomes. J Rheumatol.
- 459 2023;50(3): 300-3. doi: 10.3899/jrheum.221092.
- 460 24. Berkowitz ST, Finn AP, Parikh R, Kuriyan AE, Patel S. Ophthalmology Workforce
- 461 Projections in the United States, 2020 to 2035. Ophthalmology. 2024;131(2): 133-9. doi:
 462 10.1016/j.ophtha.2023.09.018.
- 463 25. Al-Ani HH, Sims JL, Tomkins-Netzer O, Lightman S, Niederer RL. Vision loss in
 464 anterior uveitis. Br J Ophthalmol. 2020;104(12): 1652-7. doi: 10.1136/bjophthalmol-2019-
- **465** 315551.
- 466 26. Kolomeyer AM, Crane ES, Tu Y, Liu D, Chu DS. Adult patients with uveitis
- 467 associated with juvenile idiopathic arthritis: a retrospective review. Can J Ophthalmol.
- **468** 2017;52(5): 458-62. doi: 10.1016/j.jcjo.2017.01.011.
- 469 27. Tomkins-Netzer O, Talat L, Bar A, Lula A, Taylor SR, Joshi L, Lightman S. Long-
- 470 term clinical outcome and causes of vision loss in patients with uveitis. Ophthalmology.
- 471 2014;121(12): 2387-92. doi: 10.1016/j.ophtha.2014.07.007.
- 472 28. Edelsten C, Reddy MA, Stanford MR, Graham EM. Visual loss associated with
- 473 pediatric uveitis in english primary and referral centers. Am J Ophthalmol. 2003;135(5): 676-
- 474 80. doi: 10.1016/s0002-9394(02)02148-7.

475

477 Supporting documents

- 478 Supplemental material 1: Imaging acquisition protocol
- 479 Supplemental material 2: Specific visual acuity screening protocol
- 480 Supplemental material 3: Consent and Assent forms

	Screening	Baseline	Intervention phase				Final visit	
Visit No:	1	2	3	4	5	6	7	8 or 9 ^e
Week (new diagnosis)a medRxiv preprint doi:@ttps://doi.org/10.1101/20 preprint (which was not certified by peer re	024.12.12.24318929; this version posted Dece eview) is the author/funder, who has granted	ember 13, 2024. The copyright holo medRxiv a license to display the pr	Week	Week 8	Week 16	Week 28	Week 40	Week 52
Week (recent diagnosis) ^a	perpetuity. e available under a CC-BY 4.0 International lic	cense . –		Week 13	Week 26	Week 39	-	Week 52
Window of flexibility for			+/- 7	+/- 7	+/- 7	+/- 7	+/- 7	+/- 7
timing of visits:			days	days	days	days	days	days
Informed Consent	Х							
Medical History	Х	Х						
Eligibility confirmation	Х	Х	Х					
Randomisation		Х						
History ^b		Х	Х	Х	Х	Х	Х	Х
Visual acuity ^c		Х	Х	Х	Х	Х	Х	Х
Slit lamp examination (control group)		Х	Х	х	х	х	х	х
Slit lamp examination (intervention group, new diagnosis)		х				х		х
Slit lamp examination (intervention group, recent diagnosis)		Х			х			х
OCT acquisition (intervention group) ^d			Х	х	х	х	х	х
Adverse Events review			Х	Х	Х	Х	Х	Х
Concomitant		V	х	V	х	v	х	V
Medication review		Х	^	Х	^	Х	^	Х
PedsQL child self-report			Х					Х
Visual analogue scoring of examination			х					х
procedures								

Figure 1

nttps://doi.org/10.1101/2024.12.12.24318920; this v not certified by peer review) is the author/funder perpetuity. It is made available under a conversion

Procedures at each visit for control group (i.e. standard care)

medRxiv preprint doi

2024. The copyright holder for this a license to display the preprint in

Specific intervention procedures at each visit for intervention group (italicised where interventions divert from standard care)

History: concomitant use of immunosuppression or immunomodulation (and dose)

History: any eye or visual symptoms since last visit

History: any other parental concerns

Visual acuity – measured with ageappropriate methods*: Thompson Kays, or Thompson LogMAR, in each eye separately, with correction if needed

Slit lamp assessment of anterior chamber using SUN, scores for AC cells and AC flare

Other findings on eye examination (normal or abnormal with details)

History: concomitant use of immunosuppression or immunomodulation (and dose)

History: any eye or visual symptoms since last visit

History: any other parental concerns

Visual acuity measured with ageappropriate methods*: Thompson Kays, or Thompson LogMAR, in each eye separately, with correction if needed

Anterior segment OCT acquisition:

Heidelberg Spectralis OCT2 anterior segment cube scan Heidelberg Spectralis OCT2 anterior segment single line scan

Optovue RTVue OCT anterior segment cube scan Optovue RTVue OCT anterior segment single line scan

Figure 2